New drug shows promise for tough lung cancers

NCT ID NCT04940325

Ongoing Disease control Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called DS-1062a in 100 people with advanced non-small cell lung cancer that has worsened after standard treatments. The drug is given every three weeks and aims to shrink tumors. Researchers will also study how the drug affects the immune system and look for markers that predict who benefits most. The goal is to find a better option for patients who have run out of standard therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm metastatic malignant neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED NON-SMALL CELL LUNG CANCER METASTATIC LUNG CANCER UNRESECTABLE NON-SMALL LUNG CANCER

Contacts and locations

Locations

Centre François Baclesse

Caen, 14076, France
Centre Hospitalier Intercommunal de Créteil

Créteil, 94010, France
Gustave Roussy

Villejuif, 94805, France
Hospices Civils de Lyon - Centre Hospitalier Lyon Sud

Pierre-Bénite, 69310, France
Hôpital Cochin

Paris, 75014, France
Hôpital Tenon

Paris, 75970, France
Hôpitaux Universitaires de Strasbourg

Strasbourg, 67091, France
Institut Bergonié

Bordeaux, 33076, France
Institut de Cancérologie, CHRU Morvan de Brest

Brest, 29200, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.